PRESS RELEASE published on 04/03/2024 at 14:00, 5 months 25 days ago Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults Bausch Health's UCERIS listed on public drug plans in 5 Canadian provinces. The rectal foam treats mild to moderate ulcerative colitis. Patients gaining insured access to effective treatment Ulcerative Colitis Bausch Health Canada UCERIS Public Drug Plans
BRIEF published on 04/02/2024 at 14:05, 5 months 26 days ago New Survey Reveals Over Half of IBS/CIC Patients Feel Isolated, Though Social Media Fosters Community and Healthcare Discussions Survey Social Media CIC Healthcare Communication IBS
PRESS RELEASE published on 04/02/2024 at 14:00, 5 months 26 days ago Based on a New Survey, More Than Half of Surveyed IBS/CIC Patients Feel Alone in Their Experience but Also Find That Social Media Helps Create a Community and Inspires Healthcare Provider Conversations Salix Pharmaceuticals releases fourth annual Patient Perspectives IBS Impact Report, revealing insights on the experiences of IBS/CIC patients and the need for more authentic conversations. Survey conducted in partnership with FDU Poll Salix Pharmaceuticals IBS Impact Report FDU Poll Patient Experiences Authentic Conversations
BRIEF published on 03/06/2024 at 14:05, 6 months 22 days ago Salix Pharmaceuticals Backs Phase 2 Study on RELISTOR for Head and Neck Cancer Salix Pharmaceuticals Clinical Trial Phase 2 Study RELISTOR Head And Neck Cancer
PRESS RELEASE published on 03/06/2024 at 14:00, 6 months 22 days ago Salix Pharmaceuticals Announces a Phase 2 Investigator-Initiated Study of RELISTOR(R) (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma Bausch Health Companies Inc. and Salix Pharmaceuticals are supporting a Phase 2 study of RELISTOR in head and neck cancer patients. The study aims to evaluate the potential of methylnaltrexone bromide as a treatment option Bausch Health Companies Inc. Salix Pharmaceuticals Phase 2 Study RELISTOR Head And Neck Cancer
BRIEF published on 03/05/2024 at 14:05, 6 months 23 days ago Survey Reveals Colonoscopy Preparation Concerns Among U.S. Patients Salix Pharmaceuticals Colonoscopy Patient Awareness Survey Results Preparation Process
PRESS RELEASE published on 03/05/2024 at 14:00, 6 months 23 days ago New Survey Finds More Than Half of Past U.S. Colonoscopy Patients Wish They Had Known More Information About Colonoscopies Including Prep Medication Options and How To Prepare for the Procedure Salix Pharmaceuticals releases findings from first colonoscopy awareness survey, revealing insights on patient perspectives, barriers, and healthcare provider recommendations Salix Pharmaceuticals Colonoscopy Awareness Healthcare Provider Patient Perspectives Barriers
BRIEF published on 03/01/2024 at 14:05, 6 months 27 days ago Bausch Health Companies to Present at Cowen Annual Health Care Conference Investor Relations Webcast Bausch Health Health Care Conference Cowen Annual
PRESS RELEASE published on 03/01/2024 at 14:00, 6 months 27 days ago Bausch Health Companies to Present at Cowen Annual Health Care Conference Bausch Health Companies Inc. to participate in Cowen Annual Health Care Conference on March 5, 2024, hosting a fireside chat. Webcast details provided Bausch Health Companies Inc. Investor Relations Webcast Fireside Chat Cowen Annual Health Care Conference
PRESS RELEASE published on 02/12/2024 at 14:00, 7 months 16 days ago Salix Announces 2024 Gastrointestinal Health Scholars Program Bausch Health Companies Inc. has announced the 2024 Salix Gastrointestinal Health Scholars Program, offering scholarships of up to $10,000 to 10 students with GI diseases. Applications open until May 6, 2024. Learn more at www.salix.com/scholarship Bausch Health Companies Inc. Financial Support Salix Gastrointestinal Health Scholars Program Scholarships GI Diseases
Published on 09/28/2024 at 02:06, 22 hours 17 minutes ago Global Education Communities Corp. Reports Second Tranche Closing of Non-Brokered Private Placement
Published on 09/28/2024 at 02:00, 22 hours 23 minutes ago Quantum Biopharma Provides Corporate Update
Published on 09/28/2024 at 02:00, 22 hours 23 minutes ago bettermoo(d)’s Moodrink(TM) Featured in Banners of Well-Known Canadian Retailers
Published on 09/28/2024 at 00:10, 1 day ago LQWD Technologies Announces Non-Brokered Private Placement Update
Published on 09/28/2024 at 14:01, 10 hours 22 minutes ago Turkiye Garanti Bankasi A.S.: Explanation on Subordinated Debt Securities to Qualified Investors
Published on 09/27/2024 at 22:30, 1 day 1 hour ago DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update
Published on 09/27/2024 at 21:56, 1 day 2 hours ago EQS-Adhoc: FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)
Published on 09/27/2024 at 18:50, 1 day 5 hours ago PETROFAC ANNOUNCES IN-PRINCIPLE AGREEMENT ON FINANCIAL RESTRUCTURE
Published on 09/27/2024 at 18:40, 1 day 5 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/27/2024 at 17:45, 1 day 6 hours ago NFL BIOSCIENCES: 2024 FIRST-HALF BUSINESS AND EARNINGS UPDATE
Published on 09/26/2024 at 18:00, 2 days 6 hours ago GUILLEMOT CORPORATION: Availability of the interim financial report to June 30, 2024
Published on 09/26/2024 at 18:00, 2 days 6 hours ago GUILLEMOT CORPORATION: 2024 CONSOLIDATED INTERIM RESULTS
Published on 09/26/2024 at 17:47, 2 days 6 hours ago imerys-26-September-2024-information-share-capital-and-voting-rights-as-of-31-August-2024